AUPH Stock Price | Aurinia Pharmaceuticals Inc P/E, Revenue, EPS, & Forecasts

Aurinia Pharmaceuticals Inc • AUPH

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Aurinia Pharmaceuticals Inc

Ticker

AUPH

Trading on

NASDAQ

ISIN

CA05156V1022

Industry

Biotechnology

Sector

Healthcare

CEO

Kevin C. Tang

Headquarters

#140, 14315 – 118 Avenue, Edmonton, AB, Canada, T5L 4S6

Employees

128

Website

auriniapharma.com

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Metrics

BasicAdvanced

Market cap

$2.05B

P/E ratio

7.45

EPS

$2.14

Dividend Yield

0.00%

Beta

1.42

Forward P/E ratio

18.38

EBIDTA

$154M

Ex dividend date

Price & volume

Market cap

$2.05B

Average daily volume

2.1M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

7.45

Forward P/E

18.38

PEG ratio

Trailing P/E

7.45

Price to sales

6.87

Price to book

3.61

Earnings

EPS

$2.14

EPS estimate (current quarter)

$0.20

EPS estimate (next quarter)

$0.20

EBITDA

$154M

Revenues (TTM)

$298M

Revenues per share (TTM)

$2.25

Technicals

Beta

1.42

52-week High

$19.25

52-week Low

$8.55

50-day moving average

$16.02

200-day moving average

$14.94

Short ratio

5.19

Short %

8.26%

Management effectiveness

ROE (TTM)

64.98%

ROA (TTM)

13.66%

Profit margin

99.97%

Gross profit margin

$233M

Operating margin

53.31%

Growth

Quarterly earnings growth (YoY)

56.30%

Quarterly revenue growth (YoY)

24.40%

Share stats

Outstanding Shares

129M

Float

126M

Insiders %

7.53%

Institutions %

60.65%

Analyst Insights & forecasts

84% Buy

16% Hold

0% Sell

Based on information from 6 analysts.

Average price target

$17.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

$0.16

$0.15

6.67%

Q2 • 25Beat

$0.23

$0.16

43.75%

Q3 • 25Beat

$0.26

$0.21

23.81%

Q4 • 25Beat

$0.25

$0.16

56.25%

Q1 • 26Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$77.1M

$211M

273.35%

Q4 • 25

$77.7M

$34.4M

44.21%

Q1 • 26

0.77%

-83.70%

-83.83%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$752M

$170M

22.65%

Q4 • 25

$724M

$156M

21.60%

Q1 • 26

-3.67%

-8.16%

-4.66%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$44.6M

$-36.7M

$-0.5M

$44.5M

Q4 • 25

$32.6M

$-18M

$-53.7M

$32.5M

Q1 • 26

-26.95%

-50.82%

10,396.83%

-26.92%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Aurinia Pharmaceuticals Inc share?

Aurinia Pharmaceuticals Inc shares are currently traded for undefined per share.

How many shares does Aurinia Pharmaceuticals Inc have?

Aurinia Pharmaceuticals Inc currently has 129M shares.

Does Aurinia Pharmaceuticals Inc pay dividends?

No, Aurinia Pharmaceuticals Inc doesn't pay dividends.

What is Aurinia Pharmaceuticals Inc 52 week high?

Aurinia Pharmaceuticals Inc 52 week high is $19.25.

What is Aurinia Pharmaceuticals Inc 52 week low?

Aurinia Pharmaceuticals Inc 52 week low is $8.55.

What is the 200-day moving average of Aurinia Pharmaceuticals Inc?

Aurinia Pharmaceuticals Inc 200-day moving average is $14.94.

Who is Aurinia Pharmaceuticals Inc CEO?

The CEO of Aurinia Pharmaceuticals Inc is Kevin C. Tang.

How many employees Aurinia Pharmaceuticals Inc has?

Aurinia Pharmaceuticals Inc has 128 employees.

What is the market cap of Aurinia Pharmaceuticals Inc?

The market cap of Aurinia Pharmaceuticals Inc is $2.05B.

What is the P/E of Aurinia Pharmaceuticals Inc?

The current P/E of Aurinia Pharmaceuticals Inc is 7.45.

What is the EPS of Aurinia Pharmaceuticals Inc?

The EPS of Aurinia Pharmaceuticals Inc is $2.14.

What is the PEG Ratio of Aurinia Pharmaceuticals Inc?

The PEG Ratio of Aurinia Pharmaceuticals Inc is 0.

What do analysts say about Aurinia Pharmaceuticals Inc?

According to the analysts Aurinia Pharmaceuticals Inc is considered a buy.